Fundamentals Overview
REGENXBIO Inc. is in the middle of its 52-week range with moderate valuation, trending downward today.
Valuation moderate
Risk (Beta)
0.9 — in line vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
3M vs S&P 500: +26.4% · 3M vs Healthcare sector: +29%
Pressures (Sell):
Analyst grade: D+
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: D+. Current institutional positions: Buy: 19, Neutral: 2, Outperform: 5, Overweight: 4.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-27.15; current price is $12.29. That’s a -320.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 30.56 |
| P/S (TTM) | 7.23 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.62 |
| Quick Ratio (TTM) | 2.62 |
| Cash Ratio (TTM) | 0.21 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -3.3% |
| Gross margin (TTM) | -0.14% |
| Operating margin (TTM) | -2.92% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for RGNX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-06-24 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-06-22 |
| Baird | maintain | Outperform | Outperform | 2026-06-22 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-06-05 |
| Barclays | maintain | Overweight | Overweight | 2026-05-15 |
| B of A Securities | maintain | Buy | Buy | 2026-05-15 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-09 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-03-06 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-02-10 |
| Goldman Sachs | maintain | Neutral | Neutral | 2026-02-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-10 |
| Chardan Capital | maintain | Buy | Buy | 2026-02-10 |
| Chardan Capital | maintain | Buy | Buy | 2026-01-29 |
| Stifel | maintain | Buy | Buy | 2025-12-19 |
| Leerink Partners | maintain | Outperform | Outperform | 2025-12-15 |
| Chardan Capital | maintain | Buy | Buy | 2025-11-20 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-07 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-10-07 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-09-08 |
| Chardan Capital | maintain | Buy | Buy | 2025-09-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-08-19 |
| Barclays | maintain | Overweight | Overweight | 2025-08-08 |
| Chardan Capital | maintain | Buy | Buy | 2025-08-08 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-08 |
| Chardan Capital | maintain | Buy | Buy | 2025-06-09 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-04-17 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-21 |
| Chardan Capital | maintain | Buy | Buy | 2025-03-20 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-20 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-17 |